Evidence map›Paper›PMID 34758190›Full record

ArticleEMBO reports2022

POGZ promotes homology-directed DNA repair in an HP1-dependent manner.

John Heath, Estelle Simo Cheyou, Steven Findlay, Vincent M Luo, Edgar Pinedo Carpio, Jeesan Lee, Billel Djerir, Xiaoru Chen, Théo Morin, Benjamin Lebeau and 9 more

Open access · bronzeAbstract read
In one paragraph

Article in EMBO reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Review
  3. Translational pediatrics · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

John HeathLady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.
Estelle Simo CheyouLady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.
Steven FindlayLady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.
Vincent M LuoLady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.
Edgar Pinedo CarpioLady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.
Jeesan LeeLady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.
Billel DjerirDepartment of Biology, Université de Sherbrooke, Sherbrooke, QC, Canada.
Xiaoru ChenLady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.
Théo MorinDepartment of Biology, Université de Sherbrooke, Sherbrooke, QC, Canada.
Benjamin LebeauLady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.
Martin KaramLady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.
Halil BagciInstitut de Recherches Cliniques de Montréal (IRCM), Montreal, QC, Canada.ORCID 0000-0003-2448-820X
Damien GraptonLady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.
Josie Ursini-SiegelLady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.
Jean-Francois CôtéInstitut de Recherches Cliniques de Montréal (IRCM), Montreal, QC, Canada.
Michael WitcherLady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.
Stéphane RichardLady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.ORCID 0000-0003-2665-4806
Alexandre MaréchalDepartment of Biology, Université de Sherbrooke, Sherbrooke, QC, Canada.ORCID 0000-0003-3216-6542
Alexandre OrthweinLady Davis Institute for Medical Research, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.ORCID 0000-0002-7350-3413
Jewish General Hospital · CAUniversité de Sherbrooke · CAMontreal Clinical Research Institute · CA

Funding

CIHR 159759CIHR 376245CIHR 376288
6 · The paper itself

Abstract

The heterochromatin protein HP1 plays a central role in the maintenance of genome stability but little is known about how HP1 is controlled. Here, we show that the zinc finger protein POGZ promotes the presence of HP1 at DNA double-strand breaks (DSBs) in human cells. POGZ depletion delays the resolution of DSBs and sensitizes cells to different DNA-damaging agents, including cisplatin and talazoparib. Mechanistically, POGZ promotes homology-directed DNA repair by retaining the BRCA1/BARD1 complex at DSBs in an HP1-dependent manner. In vivo CRISPR inactivation of Pogz is embryonically lethal. Pogz haploinsufficiency (Pogz

Indexed as

Chromobox Protein Homolog 5DNA RepairIntellectual DisabilityRecombinational DNA RepairTransposasesAnimalsCell Cycle ProteinsChromosomal Proteins, Non-HistoneDNADNA-Binding ProteinsDNA Breaks, Double-StrandedHumansMiceCell Cycle ProteinsChromobox Protein Homolog 5Chromosomal Proteins, Non-HistoneDNADNA-Binding ProteinsPOGZ protein, humanTransposasesDNA double-strand breakhomologous recombinationHP1POGZwhite Sutton syndrome

Identifiers

PMID34758190
PMCPMC8728601
OpenAlexW3214423460

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.